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Coronaviruses (CoVs) belong to order nidovirales, 
family coronaviridae. Human coronaviruses cause 
respiratory infections associated with influenza-like 
illness ranging from the common cold to more severe 
symptoms1. The 21st century witnessed three 
outbreaks of human deadly pneumonia 
coronaviruses; Severe Acute Respiratory Syndrome 
Coronavirus (SARS-CoV) in 2003, Middle East 
Respiratory Syndrome Coronavirus (MERS-CoV) in 
2012, and SARS-like-CoV named 2019-nCoV (also 
known as SARS-CoV-2) in December 20192,3. Genomic 
analysis on the coronavirus revealed that Bat 
coronavirus RaTG13 appears to be the closest relative 
to the SARS-CoV-2 compared to SARS-CoV4. The 
SARS-CoV-2, like other CoVs, are enveloped, positive-
sense, long single-stranded RNA viruses and translate 
two groups of proteins, i.e., structural proteins such as 
Spike (S), Nucleocapsid (N), Matrix (M), and Envelope 
(E), as well as non-structural proteins, such as 
proteases and RNA-dependent RNA polymerase 
(RdRp)5. Coronaviruses depend on RdRp for the high 
frequency of RNA recombination and are among the 
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The novel coronavirus SARS-CoV-2 is an acute respiratory tract 
infection that emerged in Wuhan city, China. The spike protein of 
coronaviruses is the main driving force for host cell recognition and is 
responsible for binding to the ACE2 receptor on the host cell and 
mediates the fusion of host and viral membranes. Recognizing 
compounds that could form a complex with the spike protein (S-
protein) potently could inhibit SARS-CoV-2 infections. The software 
was used to survey 300 plant natural compounds or derivatives for 
their binding ability with the SARS-CoV-2 S-protein. The docking 
score for ligands towards each protein was calculated to estimate the 
binding free energy. Four compounds showed a strong ability to bind 
with the S-protein (neohesperidin, quercetin 3-O-rutinoside-7-O-
glucoside, 14-ketostypodiol diacetate, and hydroxypropyl 
methylcellulose) and used to predict its docking model and binding 
regions. The highest predicted ligand/protein affinity was with 
quercetin 3-O-rutinoside-7-O-glucoside followed by neohesperidin. 
The four compounds were also tested against other related 
coronavirus and showed their binding ability to S-protein of the bat, 
SARS, and MERS coronavirus strains, indicating that they could bind 
and block the spike activities and subsequently prevent them infection 
of different coronaviruses. Molecular docking also showed the 
probability of the four ligands binding to the host cell receptor ACE2. 
The interaction residues and the binding energy for the complexes 
were identified. The strong binding ability of the four compounds to 
the S-protein and the ACE2 protein indicates that they might be used 
to develop therapeutics specific against SARS-CoV-2 and close related 
human coronaviruses. 
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main factors that cause phenotypical and genotypical 
diversity of CoVs that make them capable of jumping 
across species6. 
The homotrimeric spike glycoprotein helps the virus 
initiate the infection by attaching to the host cell 
receptor, mediates virus fusion and genome entry into 
the host cell7. It is a large type I transmembrane protein 
composed of two subunits; the S1 subunit mainly 
contains a receptor-binding domain (RBD) responsible 
for recognizing the host cell surface receptor 
angiotensin-converting enzyme 2 (ACE2) and binding 
to it. The second subunit (S2) contains the basic 
elements required for the membrane fusion and entry 
into the host cells8,9. The SARS-CoV-2 S-protein and its 
interaction with the cell receptor ACE2 have been 
studied using cryo-EM, and results confirmed the 
function of the S1 and S2 subunits10. 
The 3D atomic scale of the SARS-CoV-2 S-protein was 
recently reported, and structural evidence that it binds 
to the ACE2 with 10- to 20-fold higher affinity than the 
SARS-CoV S-protein. Binding residues between the 
RBD in SARS-CoV-2 and ACE2 were determined and 
compared to the SARD-CoV11,12. Structural analysis 
showed highly conserved or shared similar side chain 
properties with those in the SARS-CoV RBD. The 
SARS-CoV-2 has an extended insertion containing 
short β5 and β6 strands, α4 and α5 helices, and loops, 
which represent the receptor-binding motif (RBM) 
containing most of the contacting residues of SARS-
CoV-2 for ACE2 binding13,14. Two epitopes of two 
SARS-CoV antibodies targeting the RBD are also 
analyzed with the SARS-CoV-2 RBD, providing 
insights into the future identification of cross-reactive 
antibodies15. 
Scientists have focused on the SARS-CoV-2 S-protein 
as a key target for vaccines, therapeutic antibodies, and 
diagnostics. In fact, to discover a new vaccine and 
therapeutic antibody needs many years of laborious 
work16. The bioinformatics analysis approved a fast 
way to find potential molecules from the marketed 
drugs to develop a new drug against the SARS-CoV-2. 
Once the efficacy is determined, it can be approved by 
the Green Channel or approved by the hospital ethics 
committee for rapid clinical treatment17. Through this 
technology, several compounds, including natural 
plant compounds, have been screened and confirmed 
to directly inhibit the essential proteins responsible for 
viral entry and replication, such as S-protein of SARS 
or MERS coronavirus. Currently, commercial antiviral 
molecules and chemical compounds extracted from 
traditional Chinese medicinal herbs were 
investigated18,19. 
Molecular docking using AutoDock Vina is a popular 
tool used in the virtual screening of small molecules 
against proteins and is also used to investigate the 
interactions of natural products against the target 
protein20. Pharmacokinetic study and in silico 
absorption, distribution, metabolism, and excretion 
(ADME) modeling is used to speed up drug approval 
as it indicates if new compounds have side effects on 
human health21. In this study, a molecular docking 
system was performed to screen and select the binding 
affinity of the S-protein of SARS-CoV-2 as well as the 
host cell receptor ACE2 against some natural plant 
compounds or derivatives that might be used to block 
virion binding to host cells and subsequently prevent 
viral infection and spreading. 
 
METHOD 
Hardware and Software 
The hardware used is a Notebook with specification 
Intel® Core™ i3-4005U CPU@1.70 GHz, 4 GB 
memory, 64-bit Windows 7 Operating System. 
Software used includes I-TASSER from University of 
Michigan (freeware, 
https://zhanglab.ccmb.med.umich.edu/I-
TASSER/), SWISS-MODEL from Swiss Institute of 
Bioinformatics (freeware, 
https://swissmodel.expasy.org/), 3Drefine from 
University of Missouri (freeware, 
http://sysbio.rnet.missouri.edu/3Drefine/), 
SAMSON 2020 R3 1.0.0 from OneAngstrom (trial 
version, https://www.samson-connect.net/), Open 
Babel 3.1.1 from Open Babel development team 
(freeware , http://openbabel.org/wiki/Main_Page), 
SwissADME from Swiss Institute of Bioinformatics 
(freeware, http://www.swissadme.ch/), Discovery 
Studio Visualizer v20.1.0.19295 from Dassault 




MEGA-X from Pennsylvania State University 
(freeware, https://www.megasoftware.net/), Clustal 
Omega 1.2 from European Bioinformatics Institute 
(freeware, 
https://www.ebi.ac.uk/Tools/msa/clustalo/), and 
Shamkh IM, Pratiwi D. 2021. Development of SARS-CoV-2 Inhibitors Using Molecular Docking Study with Spike Protein and ACE2 
3 
ESpript 3.0 from Lyon University 
(https://espript.ibcp.fr/ESPript/ESPript/). 
Ligands 
The ligands used in this study were quercetin 3-O-
rutinoside-7-O-glucoside (PubChem ID 10190763), 
neohesperidin (232990), hydroxypropyl 





The receptor used were SARS-CoV-2 (QHD43416.1), 
SARS-GD01 (AAP51227.1), Bat coronavirus RaTG13 
(QHR63300.2), MERS (QFQ59587.1), and ACE2 
protein (PDB ID 6M0J). 
Docking protocol 
Preparation of SARS-CoV-2 S-protein structures 
The sequence of the human CoVs spikes protein of the 
SARS-CoV-2 with GenBank accession no. 
QHD43416.1 was downloaded from National Centre 
for Biotechnology Information (NCBI) database 
(https://www.ncbi.nlm.nih.gov/). The protein 
sequence was retrieved in the FASTA format as an 
amino-acid length sequence and used to build the 3D 
structure monomeric, trimeric, and trimeric binding 
models using I-TASSER. The 3D structure for the S-
protein of other CoVs was built using the SWISS-
MODEL. All water molecules and ligands were 
removed for pre-docking while hydrogen atoms were 
added to the target protein. In addition, affinity 
minimization was performed using the 3Drefine 
server. The docking system was built using SAMSON 
2020. 
Dataset and ligands selection 
The 3D structure of 300 natural and synthetic 
compounds, which drive from the natural plants with 
drug-like properties and their derivatives, were 
selected. Sub-structural features of the ligand were 
carefully selected from references and separately 
downloaded from PubChem 
(https://pubchem.ncbi.nlm.nih.gov/) in SDF format 
converted into MOL2 format using Open Babel. 
Screening with SwissADME 
Selected compound structures were converted to 
SMILES notations and submitted to the webserver for 
calculation and filtration by the SwissADME to 
identify the physicochemical features and predict the 
ADME parameters, drug-like nature, pharmacokinetic 
properties, and medicinal chemistry of the selected 
compounds. The ADME depends on collecting data 
and developing models to assess and predict 
pharmacokinetic properties. The compounds that 
become ready for docking with the target protein were 
reduced to 250 ligands using the SwissADME, 
depending upon their solubility and cytotoxicity to 
humans. 
Spike protein-ligand docking 
The SARS-CoV-2 S-protein model and other CoVs 
related to S-protein was docked against the test ligands 
using SAMSON 2020. This software used AutoDock 
Vina to maximize the accuracy of these predictions 
while minimizing the computer time. The program 
works based on quantum mechanics. It predicts the 
potential affinity, molecular structure, geometry 
optimization of the structure, vibration frequencies of 
coordinates of atoms, bond length, and bond angle20. 
Following the exhaustive search, 100 poses were 
analyzed, and the best scoring poses were used to 
calculate the binding affinity of the ligands. The 
ligands that tightly bind to a target protein with a high 
score were selected. 
ACE2-ligand docking 
The receptor protein ACE2 was downloaded from the 
RCSB protein data bank (https://www.rcsb.org/). 
Pre-docking was carried out as described using 
SAMSON 2020 and Discovery studio Visualizer. The 
17 interacting amino acid residues (Gln24, Thr27, 
Phe28, Asp30, Lys31, His34, Glu35, Glu37, Asp38, 
Tyr41, Gln42, Leu79, Met82, Tyr83, Asn330, Lys353, 
and Gly354) that represent the bounded region of the 
ACE2 to the SARS-CoV-2 S-protein were previously 
reported14 and were selected to study the interaction 
with the selected ligands using AutoDock Vina and 
SAMSON 2020 as described before. 
Assessment 
Virtual screening and docking parameter 
Virtual screening utilized docking and scoring of each 
compound from the previous dataset. This technique 
was employed based on the prediction of binding 
modes and binding affinities of each compound using 
docking to four proteins structure (experimental 
protein and 3D structure models of the other 
proteins)22. The docking program behaves to get the 
docking parameter in the SAMSON 2020, in which the 
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program could make docking for a library of ligands 
with a single protein. By considering this, diverse 
compounds from plants and protein targets were 
evaluated. In general, it was important to visualize the 
docked poses of high-scoring compounds because 
many ligands were docked in different orientations. 
This kind of study becomes difficult when the size of 
the dataset increased. Therefore, it was important to 
eliminate unuseful compounds by SwissADME 
before docking by restricting the dataset to drug-like 
compounds and taking into considerations 
appropriate property, sub-structural features, 
solubility, and cytotoxicity to be deal with human use 
and eliminate the probability of side effect to get the 
best feature of the ligands then the docking was 
placed23. Hence, the bounded ligands were analyzed 
with Discovery Studio Visualizer, which was used to 
analyze and screen the ligand properties to reach the 
functional domain of protein in the human body. 
Sequence alignment and phylogenetic tree 
The amino acid sequences for 30 CoV S-proteins were 
obtained from the NCBI database. Alignments were 
applied to build a phylogenetic tree using the Mega X. 
For this alignment and constrict tree, the MUSCLE 
algorithm was used. The phylogenetic relationships 
among the 30 spike proteins were carried out using the 
nearest-neighbour interactions (NNI) with WAG+G+I 
substitution model and 500 bootstrap replicates. To 
reach a rational phylogenic tree, we eliminated 
proteins and repetitive sequences with the same 
species. 
Multiple Sequence Alignment (MSA) of the 
phylogenetically with the closely related CoV S-
proteins sequences were used to determine the 
conserved region of these sequences by Clustal Omega 
with default parameters. In addition, the ESpript 3.0 
was used to align conserved sequences among the 
selected proteins and secondary structure of SARS-
CoV-2 S-protein. Amino acid alignment of three 
related CoVs S-proteins was performed using the 
default parameters. 
 
RESULTS AND DISCUSSION 
Sequence structure analysis SARS-CoV-2 S-protein 
Comparison of the amino acids of the SARS-CoV-2 S-
protein for the modeling (GenBank accession no. 
QHD43416.1) and the experimental one (PDB ID 
6VSB) showed that the sequences were identical in the 
N terminal for the two sequences (1208 amino acids) 
but different at the C terminal, as the modeling SARS-
CoV-2 S-protein had a longer and different sequences 
of 82 amino acids from the corresponding 62 amino 
acids of the experimental one24. 
Protein model of SARS-CoV-2 S-protein 
The predicted 3D structure of the SARS-CoV-2 S-
protein model was built with I-TASSER (Figure 1A) 
using the published sequence at the NCBI. The built 
model was compared with the experimental one 
(Cryo-EM structure) downloaded from the Protein 
Data Bank (Figure 1B). The structure of the built model 
was divided into four regions to facilitate the 
comparison with the experimental one. The two 
models showed different configurations. The folding 
in the experimental one was more compact, and region 
“iv” was not presented. From these results, it was 
important to state that although there was a similarity 
between the two models, the differences between 
these two spike proteins could mislead the scientists 
when depending on the model folding in docking 
with any compounds, and hence, the best results were 
obtained when using the experimental data25. 
The homotrimer of the experimental spike-protein for 
the SARS-CoV-2 was used to design the ligand-protein 
interactions with the four selected ligands (Figure 2) 
using the SAMSON 2020. The resembled complexes 
were analyzed using Discovery Studio Visualizer to 
resemble the ligand with the interacting residues and 









Figure 1. Comparison between the single protomer of SARS-
CoV-2 S-protein for (A) built model compared to (B) the 
experimental one. Boxes were indicating the intermolecular 
interaction with (a) 14-ketostypodiol diacetate, (b) 
neohesperidin, (c) quercetin 3-O-rutinoside-7-O-glucoside, and 
(d) hydroxypropyl methylcellulose. The two ligands in the iv 







Figure 2. The proposed binding mode of the experimental 
SARS-CoV-2 S-protein for (A) top and (B) side views in its 
homotrimer state with (a) 14-ketostypodiol diacetate, (b) 
neohesperidin, (c) quercetin 3-O-rutinoside-7-O-glucoside, and 
(d) hydroxypropyl methylcellulose. 
 
Comparison of the docking complexes of the SARS-
CoV-2 S-protein/ligands for the built model and the 
experimental structure showed high similarities for 
binding affinity (ΔG) between the built model and the 
experimental structure, although the interacting 
residues were different. However, ΔG of quercetin 3-
O-rutinoside-7-O-glucoside and neohesperidin (-16.7 
and -15.2 kcal/mol, respectively) were lower than 14-
ketostypodiol diacetate and hydroxypropyl 
methylcellulose with the same ΔG of -13.7 kcal/mol. 
The interacting residues for the phytochemicals and 
derivate compounds were identified in the two 
models, except for the 14-ketostypodiol diacetate, 
which could interact with the S-protein through Van 
der Waals interaction. The amino acids of the S-protein 
in alignment with the four ligands were presented in 
Figure 3. 
The locations of the interacting residues for the 
experimental docking complexes (Table I) showed 
that the binding of the neohesperidin and 14-
ketostypodiol diacetate might prevent the target 
protein from attaching with the host cell membrane 
(ACE2) as they were located at the S1 ectodomain 
subunit and might prevent infection process26. 
Furthermore, the active site of the spike protein S2 
ectodomain subunit residue 686 to 1237 and spike 
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protein subunit S2' residue 816 to 1237 tightly react 














Figure 3. The binding mode of the experimental SARS-CoV-2 
S-protein with (A) 14-ketostypodiol diacetate, (B) 
neohesperidin, (C) quercetin 3-O-rutinoside-7-O-glucoside, 
and (D) hydroxypropyl methylcellulose. 
These active sites mediate fusion between the virus 
and cellular membranes and allow the insertion of 
virion genetic material into the host cell27. In 
comparison, quercetin 3-O-rutinoside-7-O-glucoside 
interact with S2 and S2' ectodomain subunits of the 
SARS-CoV-2 S-protein and might act as an inhibitor 
for S2 and S2' ectodomain subunits and prevent virus 
fusion and entry into the host cell. Therefore, these 
ligands might act as anti-SARS-CoV-2 if introduced 
into the target host cells28,29. 
 
Table I. Comparisons between the SARS-CoV-2 SARS-











































































































































































































































































































































*Van der Waals interactions do not occur with amino acid residues 
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Identifying sequence related to SARS-CoV-2 S-protein 
To identify if the four ligands were specific for docking 
with the SARS-CoV-2 S-protein only or other related 
viruses, the most related S-protein of the near CoVs 
that infect humans was selected for the ligands 
docking analysis. For selecting the CoV S-proteins, 
phylogenetic analysis was carried out with 30 CoV 
isolates (Figure 4). According to different species and 
their host, the constructed tree divided the CoVs 
sequences (human or bat). The S-protein was highly 
divergent from other CoVs with less than 77% identity 
with SARS-CoV-2, except the Bat-RaTG13 S-protein, 
which showed the close phylogenetic relationship to 
the SARS-CoV-2 S-protein, indicating that the virus 
might originate from bats30,31. 
 
 
Figure 4. Phylogenetic tree based on amino acid sequences of 
CoVs S-proteins. The scale bars represent 0.1 substitutions per 
nucleotide position. 
 
From human infection CoVs, one isolate was selected 
from each of the two most related clusters, i.e., Bat-
RaTG13 (QHR63300.2), SARS-GD01 (AAP51227.1), 
and one from out-group MERS (QGV13484.1) to study 
their docking ability with the test ligands32. The amino 
acid sequence revealed that the Bat-RaTG13 S-protein 
sequence was the closest to SARS-CoV-2 S-protein 
with 97.41% identity. In contrast, SARS-GD01 and 
MERS show only 76.19% and 35% identity, 
respectively, against SARS-CoV-2 S-protein. 
Docking test ligands with different CoVs S-proteins 
Two close related S-proteins (Bat-RaTG13 and SARS-
GD01) to SARS-CoV-2 and one out-group (MERS) 
were used to study the binding abilities with the test 
ligands33. The binding models of the four ligands with 
the target protein surface were presented in Figure 5. 
The binding ΔG that reflects the interaction between 
the test ligand and S-protein of each CoVs was 
calculated and presented in Table I. Results show that 
four ligands might have the ability to bind with high 
affinities to the CoVs, indicating that those ligands 
may have a wide range of binding to the S-protein of 
CoVs34,35. 
For SARS-CoV-2 S-protein, the best ligand was 
quercetin 3-O-rutinoside-7-O-glucoside that bind to 
protein active side residues (Tyr-756, Phe-970, Thr-998, 
Gly-999) with a ΔG of -16.7 kcal/mol in the S2 subunit 
of the protein, followed by neohesperidin, which bind 
to S1, S2 subunit with ΔG of -15.2 kcal/mol and 
interact in the active side (Thr-547, Thr-549, Thr-587, 
Thr-673, Phe-855), then 14-ketostypodiol diacetate that 
binds in the S1 subunit with ΔG of -13.7 kcal/mol but 
without direct binding with the amino acids residues 
(structurally constrained binding), and 
hydroxypropyl methylcellulose which bind in the S1, 
S2 subunit with ΔG of -13.7 kcal/mol. 
For SARS-GD01 S-protein, quercetin 3-O-rutinoside-7-
O-glucoside interacts with four active site residues, 
including Tyr-144, Cys-176, Gly-177, His-208, Pro-210, 
Asp-213, Cys-214, and Glu-247 (Figure 6). Quercetin 3-
O-rutinoside-7-O-glucoside showed the lowest ΔG (-
18.1 kcal/mol), while neohesperidin, 14-ketostypodiol 
diacetate, and hydroxypropyl methylcellulose were 
showed ΔG of -16.3, -13.8, and -11.7 kcal/mol, 
respectively. All ligands bind in the S1 subunit of the 
SARS-GD01 S-protein, which was responsible for 
initiating infection of the virion to the host cell. The 
binding sites of hydroxypropyl methylcellulose and 
quercetin 3-O-rutinoside-7-O-glucoside were 
overlapped. Therefore, a complex of the S-protein with 
the bind two ligands would form (Figure 6). 
In the Bat-RaTG13 S-protein, the highest ligand 
binding score was quercetin 3-O-rutinoside-7-O-
glucoside, which interacts with six active site residues, 
including Ser-726, Thr-774, Pyp-859, Asp-863, His-
1054, and Gly-1055 with ΔG of -17.3 kcal/mol. The 14-
ketostypodiol diacetate and neohesperidin had ΔG of 
-13.9 and -13.6 kcal/mol, respectively, and bound to 
the S2 subunit. Meanwhile, hydroxypropyl 
methylcellulose had the highest ΔG of -11.7 kcal/mol) 
and showed binding interacting with His-245 and Thr-
250. Results show the potential of all ligands fit within 
the S1 and S2 subunits and could work as inhibitors for 
Bat-RaTG13. Because the binding sites of quercetin 3-
O-rutinoside-7-O-glucoside and 14-ketostypodiol 
diacetate were overlapped, the two ligands could bind 
together before binding to the S-protein (Figure 6). 
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Figure 5. Upper: The 3D structure of the viral S-proteins for SARS-CoV-2, SARS-GD01, Bat-RaTG13, and MERS was showing the 
binding sites with (A) hydroxypropyl methylcellulose, (B) neohesperidin, (C) quercetin 3-O-rutinoside-7-O-glucoside, and (D) 14-








Figure 6. The binding models of ligands in S-protein. (A) Bat-
RaTG13 with quercetin 3-O-rutinoside-7-O-glucoside and 14-
ketostypodiol diacetate were bind in a complex to increase the 
stability. (B) SARS-GD01 with hydroxypropyl methylcellulose 
and quercetin 3-O-rutinoside-7-O-glucoside to determine the 
complex which were more relevant to the binding site. (C) 
MERS with neohesperidin, quercetin 3-O-rutinoside-7-O-
glucoside, and 14-ketostypodiol diacetate in a complex of three 
ligand were more stable. 
For the MERS S-protein, the hydroxypropyl 
methylcellulose interacts with three active site 
residues of the S-protein, including Val-54, Pro-282, 
and Asp-613. Hydroxypropyl methylcellulose binds 
with the ΔG of -12.8 kcal/mol. The quercetin 3-O-
rutinoside-7-O-glucoside, neohesperidin, and 14-
ketostypodiol diacetate bind to S-protein with ΔG of -
16.4, -14.7, and -15.2 kcal/mol, respectively. The S-
protein active sites of those three ligands were 
overlapped; adding them together to the S-protein of 
MERS would form tri-compounds and bind to the 
active site. All ligands fit with the active sites of the 
protein, which was responsible for initiating the 
infection processes36. The atomic-level structural of S-
protein for Bat-RaT13, SARS-GD01, and MERS with 
the different compounds were presented in Figure 7. 
Docking test ligands with ACE2 
The molecular docking of four ligands with ACE2 was 
performed to determine whether they strongly bind to 
the S-protein only or its cell receptor as well. Results 
obtained from molecular docking showed that the 
four ligands were able to interact with high scores to 
the ACE2 receptor, as shown in Figure 8. Table II 
summarizes the number of contacting residues, 
domain residues, interacting residues, interaction 
mode, and ΔG. 
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Figure 7. The atomic-level structural of S-protein for Bat-RaT13, SARS-GD01, and MERS with the same binding site, with the ligands of 
(A) 14-ketostypodiol diacetate, (B) neohesperidin, (C) quercetin 3-O-rutinoside-7-O-glucoside, and (D) hydroxypropyl methylcellulose. 
 
The 14-ketostypodiol diacetate showed the lowest ΔG 
(-10.6 kcal/mol), binds to eight residues of ACE2 and 
interacted with residues in seven different modes 
((Gln-24, Tyr-83), (Thr-27), (Phe-28), (Asp-30), (Glu-
35), (Glu-37), (Tyr-41)). Hydroxypropyl 
methylcellulose tightly bound to nine residues of 
ACE2 and interacted with residues in four different 
modes ((Phe-28, Asp-30, Glu-35), (Asp-30, Lys-31, Glu-
35), (Glu-37, Tyr-41, Glu-42), (Glu-37, Tyr-41, Glu-354)) 
with ΔG of -9.8 kcal/mol. Docking analysis showed 
that quercetin 3-O-rutinoside-7-O-glucoside tightly 
bound to 11 residues of ACE2 and interacted with 
residues in seven different modes ((Phe-28, His-34), 
(Asp-30, Glu-37), (Lys-31, Glu-35, Tyr-83), (Glu-37, 
Asn-330, Glu-354), (Asp-30, Lys-31), (Glu-37, Tyr-41), 
(Glu-37, Tyr-41, Glu-354), (Phe-28, Glu-42)) with ΔG of 
-9.4 kcal/mol. For the last, neohesperidin showed that 
it tightly binds to 14 residues of ACE2 and interacted 
with residues in 11 different modes ((Phe-28), (Glu-24, 
Thr-27, Phe-28, Asp-30), (Phe-28, Glu-35), (Phe-28, 
Glu-37), (Asp-30, Lys-31), (Asp-30, His-34, Glu-37), 
(Glu-37, Tyr-41, Gln-42), (Gln-42, Gly-354), (Phe-28, 
Leu-79), (Gln-24, Phe-28, Asp-30, Tyr-38), (Gly354)) 
with ΔG of -8.2 kcal/mol. 
The molecular docking showed that out of 300 natural 
plant and plant derivative compounds from the 
PubChem database, only four could bind with the 
SARS-CoV-2 S-protein with high affinity. These 
ligands were natural plant products, so they were 
considered to be safe for humans37.  The SwissADME 
server was used to analyze the solubility and 
cytotoxicity of those compounds. Also, the isolation of 
these compounds from their plants was well 
established38-40. Previous publications also showed 
that plant phytochemicals were predicted to be a 
potent inhibitor of the SARS-CoV-2 protease using 
homology modeling41. Six citrus flavonoids 
(naringenin, naringin, hesperetin, hesperidin, 
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neohesperidin, and nobiletin) were used for molecular 
docking and predicting ΔG with the ACE2. However, 
the results show that the ΔG required for the binding 











Figure 8. Molecular interaction between RBD of the ACE2 
with (A) 14-ketostypodiol diacetate, (B) neohesperidin, (C) 
quercetin 3-O-rutinoside-7-O-glucoside, and (D) 
hydroxypropyl methylcellulose. 
 
Comparison of the docking results between the SARS-
CoV-2 S-protein to the built model and the 
experimental SARS-CoV-2 S-protein with the four 
ligands revealed that the binding residues were 
different, although there was no significant difference 
in the ΔG. In this respect, the four ligands were tested 
for their binding ability with other related human 
CoVs44. From the phylogenetic evaluation for the S-
proteins of 30 CoVs, two closely related to SARS-CoV-
2 S-protein, the Bat-RaTG13 (97.41% identity) and 
SARS-GD01 (76.19% identify) was selected. In 
addition, the MERS showed only 35% identity as an 
out-group protein. Alignment of the three related 
CoVs showed that they share consensus position and 
structural domains, such as the N-terminal domain 
(NTD), the RBD, heptad-repeat regions (HR), central 
helix (CH), and circular dichroism (CD). Docking 
analysis of the CoVs S-proteins and the four ligands 
showed that they all could strongly bind to the S-
proteins with low ΔG, but the quercetin 3-O-
rutinoside-7-O-glucoside showed the lowest ΔG for 
SARS-CoV-2 (-16.7 kcal/mol), MERS (-16.4 kcal/mol), 
Bat-RaTG13 (-17.3 kcal/mol), and SARS-GD01 (-18.1 
kcal/mol). 
In ACE2, docking to the four ligands showed slight 
differences in ΔG ranged between -10.6 to -8.2 
kcal/mol. Quercetin 3-O-rutinoside-7-O-glucoside 
displayed the lowest ΔG to ACE2, while the highest 
one was neohesperidin. Binding the ligands to the host 
cell receptor will decrease the rate of viral infection45. 
The homotrimer of SARS-CoV-2 S-protein was 
modeled, and the 3D structure of the experimental one 
Shamkh IM, Pratiwi D. 2021. Development of SARS-CoV-2 Inhibitors Using Molecular Docking Study with Spike Protein and ACE2 
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was compared and showed slight differences between 
them. Although protein structure homology modeling 
had become a routine technique to generate 3D 
models for proteins, it was not accurate as of the 
experimental structures46. 
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CONCLUSION 
The four ligands, quercetin 3-O-rutinoside-7-O-
glucoside, neohesperidin, 14-ketostypodiol diacetate, 
and hydroxypropyl methylcellulose are predicted to 
be potent inhibitors for both S-protein and ACE2. 
Based on satisfactory results obtained from the 
molecular docking for ligand/S-protein and 
ligand/ACE2, we demonstrate the ability of the four 
ligands to be used as a prophylactic medication in 
COVID-19 prevention. 
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